Last reviewed · How we verify

GSK MMR Vaccine (PRIORIX)

Shanghai Institute Of Biological Products · Phase 3 active Biologic

GSK MMR Vaccine (PRIORIX) is a Live attenuated vaccine Biologic drug developed by Shanghai Institute Of Biological Products. It is currently in Phase 3 development for Prevention of measles, mumps, and rubella in children and adults.

PRIORIX is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.

PRIORIX is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.

At a glance

Generic nameGSK MMR Vaccine (PRIORIX)
SponsorShanghai Institute Of Biological Products
Drug classLive attenuated vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This immunological memory protects against infection with wild-type viruses upon future exposure. The vaccine is administered intramuscularly or subcutaneously and typically provides lifelong immunity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK MMR Vaccine (PRIORIX)

What is GSK MMR Vaccine (PRIORIX)?

GSK MMR Vaccine (PRIORIX) is a Live attenuated vaccine drug developed by Shanghai Institute Of Biological Products, indicated for Prevention of measles, mumps, and rubella in children and adults.

How does GSK MMR Vaccine (PRIORIX) work?

PRIORIX is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.

What is GSK MMR Vaccine (PRIORIX) used for?

GSK MMR Vaccine (PRIORIX) is indicated for Prevention of measles, mumps, and rubella in children and adults.

Who makes GSK MMR Vaccine (PRIORIX)?

GSK MMR Vaccine (PRIORIX) is developed by Shanghai Institute Of Biological Products (see full Shanghai Institute Of Biological Products pipeline at /company/shanghai-institute-of-biological-products).

What drug class is GSK MMR Vaccine (PRIORIX) in?

GSK MMR Vaccine (PRIORIX) belongs to the Live attenuated vaccine class. See all Live attenuated vaccine drugs at /class/live-attenuated-vaccine.

What development phase is GSK MMR Vaccine (PRIORIX) in?

GSK MMR Vaccine (PRIORIX) is in Phase 3.

What are the side effects of GSK MMR Vaccine (PRIORIX)?

Common side effects of GSK MMR Vaccine (PRIORIX) include Injection site reactions (pain, redness, swelling), Fever, Rash, Parotitis, Arthralgia/arthritis.

Related